- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05919420
White-coat Hypertension in Childhood - Effects on Blood Pressure and Organ Damage (WCH)
White coat hypertension, WCH means that the blood pressure are above normal values only when measured at visits to the doctor, but not at home. WCH has in adults proved to be predisposing to the development of hypertension, and damage to the heart and arteries. It is not known if children and young people run the same risk as adults with WCH.
The investigators have previously examined the blood pressure of 1473 healthy children and adolescents in the study "Screening for high blood pressure and silent kidney disease in school children" and the results were published recently in the American Journal of Hypertension. In the study, we identified a number of participants who had the WCH.
The investigators are implementing now, 10 years later, a follow-up study to investigate if these children with WCH have an increased risk of hypertension and subsequent cardiovascular disease. The goal is to investigate whether these young individuals are at similar risk as adults with WCH for hypertension and impaired cardiovascular function.
The investigators will provide our WCH participants extended examinations of the heart, blood vessels and kidney function, which will provide important information as to whether there are effects on cardiovascular health already in adolescence among participants that suffered from WCH in childhood. This is important knowledge in clinical work in order to learn how to best care for these children to minimize their risk of future disease.
Study Overview
Status
Conditions
Detailed Description
This is a longitudinal study in which all patients with WCH who previously participated in the above-mentioned study are included. The PI will offer the participants an outpatient check-up, which means:
- measurement of blood pressure with ambulatory blood pressure measurement during 24 hours to study blood pressure level and variation in blood pressure during the day.
- ultrasound examination of the structure and function of the heart
- ultrasound examination of blood vessels for calculation of intima-media thickness
- investigation of vessel elasticity with pulse wave analysis with Arteriograph.
- analysis of blood and urine to examine kidney function.
- Questionnaire about eating habits and physical activity
These examinations will be carried out at the Physiology Clinic, Karolinska University Hospital, Huddinge. Both ultrasound examination of blood vessels and pulse wave velocity are non-invasive examinations and provide important information about the patient's vascular status. We will take a venous blood sample (approx. 5 ml) for analysis of standard markers for organ damage and vascular function (creatinine, urate, urea, cystatin C) and a urine sample (urine albumin/creatinine). These standard measurements and sampling involve a minimal impact on the individual and the subsequent analysis methods are well developed and have been applied in several previous studies. We will also ask questions about lifestyle, which is part of the doctor's medical history. In cases where hypertension, with or without organ damage, is verified, the persons will be referred further to pediatric nephrology or to adult medicine.
The sampling is recorded according to usual routines and the participation in the study is also indicated.
Each participant is assigned a code number. Some patient-related clinical data will be recorded, such as body measurements and analysis results from blood sampling. Questionnaire responses and results from examinations from cardiac echocardiography, vascular doppler and pulse wave velocity are coded. The code list is kept separately in a locked space. Participating researchers all have access to the code list. During data processing, only coded information is used.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- being identified in our previous study as having WCH
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypertension
Time Frame: at follow up (average 9,3 years after baseline)
|
blood pressure at hypertensive level
|
at follow up (average 9,3 years after baseline)
|
Left ventricular hypertrophy
Time Frame: at follow up (average 9,3 years after baseline)
|
echocardiographic measurment
|
at follow up (average 9,3 years after baseline)
|
vascular elasticity
Time Frame: at follow up (average 9,3 years after baseline)
|
pulse wave velocity
|
at follow up (average 9,3 years after baseline)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WCH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on White Coat Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
University Hospital of CologneUnknownNAFLD; Hypertension, White-coat Hypertension, Masked HypertensionGermany
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Regional Hospital HolstebroCompletedHealthy | White Coat Hypertension | Essential HypertensionDenmark
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUnknownWhite Coat Hypertension | Blood Pressure | Lifestyle Risk ReductionIsrael, Greece, Belgium, Germany, Armenia, Austria, Bulgaria, Croatia, Czechia, Estonia, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Spain, Sweden, Ukraine, United Kingdom
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationCompletedHypertension | Obesity | White Coat Hypertension | Resistant HypertensionSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedOptimize PBSC Harvest Through Automated Buffy CoatItaly
-
University of JordanUnknownPink and White Esthetic Scores | Patient Outcome Measures
-
CIBA VISIONUniversity of WaterlooCompletedWhite Blood CellsCanada
-
Universitat Internacional de CatalunyaCompleted